Patents Represented by Attorney, Agent or Law Firm John P. White
-
Patent number: 6608106Abstract: This invention provides a method for increasing the concentration of ascorbic acid in the cells of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in the subject's cells. This invention further provides a method for increasing the antioxidant potential of the cells of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the antioxidant potential of the subject's cells. This invention also provides a method for increasing the concentration of ascorbic acid in brain tissue of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in the subject's brain tissue.Type: GrantFiled: June 13, 2001Date of Patent: August 19, 2003Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David B. Agus, Juan C. Vera, David W. Golde
-
Patent number: 6605030Abstract: An apparatus and method for treating a disease process in a luminal structure comprises a balloon catheter having a central balloon and two edge balloons. The central balloon may be separately inflated temporally and with different radioactive fluid than the edge balloons. Other arrangements include a wire, stent and concentric balloons, which provide spatial and temporal control enabling differential radioactivity at different spatial locations along the structure.Type: GrantFiled: November 9, 1998Date of Patent: August 12, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventor: Judah Z. Weinberger
-
Patent number: 6602888Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.Type: GrantFiled: November 22, 1999Date of Patent: August 5, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig
-
Patent number: 6600084Abstract: A discharge tube (11) made of a dielectric material extends through a hole (3) of a rectangular waveguide (1) and through a coaxial microwave cavity (4) so as to be coaxial with the central axis of the cavity (4). This discharge tube (11) has a double-tube structure including an outer tube (12) and an inner tube (13). The sectional area of an annular gap formed between the outer tube (12) and the inner tube (13) is held constant over the entire length of the inner tube (13). This allows the generation of a stable thermal plasma when a reaction gas containing an organic halide and water vapor is supplied into the outer tube through the annular gap with a microwave transmitted from the rectangular waveguide (1) into the cavity (4).Type: GrantFiled: December 12, 2001Date of Patent: July 29, 2003Assignee: Mitsubishi Heay Industries, Ltd.Inventors: Tetsuya Ikeda, Minoru Danno
-
Patent number: 6596475Abstract: This invention provides a vector comprising a nucleic acid which encodes a polypeptide of interest linked to one or more nucleic acid segments encoding at least two Green Fluorescent Proteins. Provided is the method for detecting a polypeptide of interest in a living cell which comprises: (a) transfecting the living cell with an isolated nucleic acid which encodes the polypeptide of interest linked to at least two Green Fluorescent Proteins. Additional polypeptides different from the polypeptide of interest may also be linked to at least two molecules of Green Fluorescent Protein; (b) culturing the transfected cell in conditions permitting expression of Green Fluorescent Protein and the polypeptide of interest; and (c) detecting the fluorescence of the Green Fluorescent Protein, thereby detecting the polypeptide of interest in a cell.Type: GrantFiled: April 12, 2001Date of Patent: July 22, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventor: Jeannette Chloe Bulinski
-
Patent number: 6593137Abstract: This invention provides a hybridoma produced by the fusion of a mouse antibody-producing cell and a mouse myeloma which is designated 1-10F-8A and deposited with the ATCC under Accession Number PTA-279, said hybridoma producing a monoclonal antibody which binds to fullerene C60. This invention provides a mouse monoclonal antibody specific for a fullerene-C60 and produced by the mouse monoclonal antibody-producing hybridoma designated 1-10F-8A. The invention provides the amino acid and encoding nucleic acid sequences of the heavy and light chains of the 1-10F-8A monoclonal antibody. This invention also provides methods of determining a serum concentration of a fullerene in a subject and of purifying a fullerene from a sample.Type: GrantFiled: August 31, 1999Date of Patent: July 15, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Bernard F. Erlanger, Bi-Xing Chen
-
Patent number: 6592869Abstract: The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.Type: GrantFiled: February 28, 2001Date of Patent: July 15, 2003Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Gilad Gallili, Norbert Frydman
-
Patent number: 6592868Abstract: This invention provides methods of treating autoimmune diseases, including those selected from the group consisting of rheumatoid arthritis, Myasthenia gravis, systemic lupus erythematosus, Graves' disease, idiopathic thrombocytopenia purpura, hemolytic anemia and diabetes mellitus with 5C8-specific antibodies.Type: GrantFiled: June 7, 1995Date of Patent: July 15, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Seth Lederman, Leonard Chess, Michael J. Yellin
-
Patent number: 6593507Abstract: A discharge tube (11) made of a dielectric material extends through a hole (3) of a rectangular waveguide (1) and through a coaxial microwave cavity (4) so as to be coaxial with the central axis of the cavity (4). This discharge tube (11) has a double-tube structure including an outer tube (12) and an inner tube (13). The sectional area of an annular gap formed between the outer tube (12) and the inner tube (13) is held constant over the entire length of the inner tube (13). This allows the generation of a stable thermal plasma when a reaction gas containing an organic halide and water vapor is supplied into the outer tube through the annular gap with a microwave transmitted from the rectangular waveguide (1) into the cavity (4).Type: GrantFiled: December 12, 2001Date of Patent: July 15, 2003Assignee: Mitsubishi Heavy Industries, Ltd.Inventors: Tetsuya Ikeda, Minoru Danno
-
Patent number: 6589733Abstract: The present invention provides a method of transcriptionally modulating the expression of a gene of interest, the expression of which is associated with a defined physiological or pathological effect within a multicellular organism. The method comprises contacting a cell which is capable of expressing the gene with an amount of a molecule effective to transcriptionally modulate expression of the gene and thereby affect the level of the protein encoded by the gene which is expressed by the cell. Molecules useful in the practice of the invention are characterized as follows (a) do not naturally occur in the cell, (b) specifically transcriptionally modulate expression of the gene of interest, and (c) bind to DNA or RNA or bind to a protein through a domain of such protein which is not a ligand binding domain of a receptor which naturally occurs in the cell, the binding of a ligand to which ligand binding domain is normally associated with the defined physiological or pathological effect.Type: GrantFiled: June 5, 1995Date of Patent: July 8, 2003Assignee: Osi Pharmaceuticals, Inc.Inventors: J. Gordon Foulkes, Robert Franco, Franz Leichtfried, Christian Pieler, John R. Stephenson
-
Patent number: 6590109Abstract: A method of isolating terpene trilactones from Ginkgo biloba plant material or extract comprising the steps of suspending the plant material or extract in either water or an aqueous solution of an oxidation reagent; extracting the terpene trilactones using an acceptable extraction agent; separating the organic layer from the aqueous layer; washing the organic layer with an acceptable aqueous salt or hydroxide solution, which may be an alkaline solution; and drying the organic layer to form a dried extract containing terpene trilactones. Further purification by treatment with or filtration over activated charcoal, by treatment with or filtration over alumina and by recrystallization with an acceptable solvent or solvent mixture leads to extracts with a content of terpene trilactones higher than 50%. Unwanted levels of ginkgolic acids are reduced to acceptable levels by reversed phase chromatography.Type: GrantFiled: July 11, 2002Date of Patent: July 8, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Dirk Lichtblau, Nina Berova, John Berger, Koji Nakanishi
-
Patent number: 6586191Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: July 23, 1997Date of Patent: July 1, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Kelli E. Smith, David Linemeyer, Christophe P. G. Gerald, Theresa Branchek, Richard L. Weinshank, Carlos Forray
-
Patent number: 6586394Abstract: This invention is directed to a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Clu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide. The invention is also directed to methods which comprise administering to a subject an effective amount of the chromatographically recovered so as to thereby inhibit the growth of epithelial cells, or heal the wound or treat the burn.Type: GrantFiled: January 27, 1994Date of Patent: July 1, 2003Assignee: OSI Pharmaceuticals, Inc.Inventors: Kenneth K. Iwata, John R. Stephenson, Leslie I. Gold
-
Patent number: 6583340Abstract: Plants, particularly transgenic plants, may be produced having a 2-acyltransferase enzyme from Limnanthes with an altered substrate specificity compared to the native enzyme. For example, oil seed rape (Brassica napus) may contain the 2-acyltransferase transgene derived from Limnanthes douglasii in order to produce trierucin. The cDNA sequence of Limnanthes douglasii 2-acyltransferase and its equivalents protein sequence are disclosed.Type: GrantFiled: March 14, 1997Date of Patent: June 24, 2003Assignee: Gene Shears Pty. LimitedInventors: Antoni Ryszard Slabas, Adrian Paul Brown, Clare Louise Brough, Johannes Theodorus Maria Kroon
-
Patent number: 6576659Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.Type: GrantFiled: December 5, 1997Date of Patent: June 10, 2003Assignee: Bio-Technology General Corp.Inventor: Don Fishbein
-
Patent number: 6576812Abstract: The present invention provides a method of identifying a composition, a compound or a procedure which can produce a skin response in a subject, and a method of identifying a composition, a compound, or a procedure which can reduce or treat skin response in a subject. The present invention further provides a method of identifying a composition, a compound, or a procedure which can reduce radiation damage to the skin of a subject, and a pharmaceutical composition for treating human skin diseases.Type: GrantFiled: May 6, 1999Date of Patent: June 10, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventor: B. Jack Longley
-
Patent number: 6569432Abstract: This invention provides an isolated nucleic acid molecule encoding an alternatively spliced human prostate-specific membrane antigen. This invention provides an isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen. This invention provides an isolated polypeptide having the biological activity of an alternatively spliced prostate-specific membrane antigen. This invention provides a method of detecting a nucleic acid encoding an alternatively spliced human prostate-specific membrane antigen and a method of detecting a prostate tumor cell in a subject. Lastly, this invention provides a pharmaceutical composition comprising a compound in a therapeutically effective amount and a pharmaceutically acceptable carrier and a method of making prostate cells susceptible to a cytotoxic chemotherapeutic agent.Type: GrantFiled: August 29, 1996Date of Patent: May 27, 2003Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair, Ouathek Ouerfelli, John Pinto
-
Patent number: 6569856Abstract: This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: January 3, 2002Date of Patent: May 27, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, Stewart A. Noble, Mahesh N. Desai
-
Patent number: 6570000Abstract: A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, which are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution may be administered to a subject infected with a human immunodeficiency virus so as to block the human immunodeficiency virus from binding to T4+ cells. Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.Type: GrantFiled: June 6, 1995Date of Patent: May 27, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Paul J. Maddon, Dan R. Littman, Leonard Chess, Richard Axel, Robin Weiss
-
Patent number: 6566092Abstract: This invention provides an isolated nucleic acid molecule encoding a vhh-1 protein, an isolated protein which is a vhh-1 protein, vectors comprising an isolated nucleic acid molecule encoding a vhh-1 protein, mamunalian cells comprising such vectors, antibodies directed to a vhh-1 protein, nucleic acid probes useful for detecting a nucleic acid molecule encoding a vhh-1 protein, pharmaceutical compositions related to the vhh-1 proteins, nonhuman transgenic animals which express a normal or a mutant vhh-1 protein. This invention further provides methods for inducing differentiation of floor plate cell, motor neuron, generating ventral neurons and treatments for alleviating abnormalities associated with the vhh-1 protein.Type: GrantFiled: February 27, 1997Date of Patent: May 20, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Thomas M. Jessell, Jane Dodd, Henk Roelink, Thomas Edlund